Japan­ese biotech pitch­ing iP­SC-de­rived med for the heart gains $26M; An­dreessen Horowitz leads $4.1M seed fund­ing for AI up­start

→ A long­time re­searcher in car­diac re­gen­er­a­tive med­i­cine has closed a $26 mil­lion Se­ries B to ad­vance his de­vel­op­ment of iP­SC-de­rived car­diomy­ocytes as a treat­ment …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER